| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Perspective |
Biometric Research Branch, National Cancer Institute, Bethesda, Maryland
Purpose: Genomic technologies make it increasingly possible to identify patients most likely to benefit from a molecularly targeted drug. This creates the opportunity to conduct targeted clinical trials with eligibility restricted to patients predicted to be responsive to the drug.
Experimental Design: We evaluated the relative efficiency of a targeted clinical trial design to an untargeted design for a randomized clinical trial comparing a new treatment to a control. Efficiency was evaluated with regard to number of patients required for randomization and number required for screening.
Results: The effectiveness of this design, relative to the more traditional design with broader eligibility, depends on multiple factors, including the proportion of responsive patients, the accuracy of the assay for predicting responsiveness, and the degree to which the mechanism of action of the drug is understood. Explicit formulas were derived for computing the relative efficiency of targeted versus untargeted designs.
Conclusions: Targeted clinical trials can dramatically reduce the number of patients required for study in cases where the mechanism of action of the drug is understood and an accurate assay for responsiveness is available.
This article has been cited by other articles:
|
|
 |
|
  Xian Zhou, Suyu Liu, E. S Kim, R. S Herbst, and J J. Lee Bayesian adaptive design for targeted therapy development in lung cancer -- a step toward personalized medicine Clinical Trials, June 1, 2008; 5(3): 181 - 193. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Sargent and D. F. Hayes Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters? J. Clin. Oncol., April 20, 2008; 26(12): 1922 - 1923. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jiang, B. Freidlin, and R. Simon Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Defined Subset Effect J Natl Cancer Inst, July 4, 2007; 99(13): 1036 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. O'Dwyer, S. G. Eckhardt, D. G. Haller, J. Tepper, D. Ahnen, S. Hamilton, A. B. Benson III, M. Rothenberg, N. Petrelli, H.-J. Lenz, et al. Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups J. Clin. Oncol., June 1, 2007; 25(16): 2313 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yancovitz, J. Yoon, M. Mikhail, W. Gai, R. L. Shapiro, R. S. Berman, A. C. Pavlick, P. B. Chapman, I. Osman, and D. Polsky Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma J. Mol. Diagn., April 1, 2007; 9(2): 178 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Stadler The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents Mol. Cancer Ther., April 1, 2007; 6(4): 1180 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Jorgensen, K. V. Nielsen, and B. Ejlertsen Pharmacodiagnostics and Targeted Therapies--A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer Oncologist, April 1, 2007; 12(4): 397 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Asgharzadeh, R. Pique-Regi, R. Sposto, H. Wang, Y. Yang, H. Shimada, K. Matthay, J. Buckley, A. Ortega, and R. C. Seeger Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification. J Natl Cancer Inst, September 6, 2006; 98(17): 1193 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Johnson Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Freidlin and R. Simon Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients Clin. Cancer Res., November 1, 2005; 11(21): 7872 - 7878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Walgren, M. A. Meucci, and H. L. McLeod Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up? J. Clin. Oncol., October 10, 2005; 23(29): 7342 - 7349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Simon Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers J. Clin. Oncol., October 10, 2005; 23(29): 7332 - 7341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Epstein Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment Clin. Cancer Res., August 1, 2005; 11(15): 5337 - 5341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Lee and L. Feng Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future Directions J. Clin. Oncol., July 1, 2005; 23(19): 4450 - 4457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Baker, T. Dragovich, N. T. Ihle, R. Williams, C. Fenoglio-Preiser, and G. Powis Stability of Phosphoprotein as a Biological Marker of Tumor Signaling Clin. Cancer Res., June 15, 2005; 11(12): 4338 - 4340. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
